ALLR earnings: next report 2026-08-21, real EPS beat/miss history, analyst consensus Buy, P/E -1.78. Updated 2026-07-23.
Allarity Therapeutics (ALLR) Research Hub
Allarity Therapeutics (ALLR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.22 USD (-3.17%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.78, market cap 0.02B. This hub links to the full technical, earnings and options research available for ALLR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.22 USD (-3.17%) |
| 52-week range | 1.03 USD – 1.55 USD |
| Trend regime | Range |
| 14-day RSI | 36.9 (Bearish) |
| Trailing P/E | -1.78 |
| Market cap | 0.02B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-21 |
Available research for ALLR
Covered Call on ALLR: how it works, illustrative setup around the real 1.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ALLR: how it works, illustrative setup around the real 1.22 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ALLR: how it works, illustrative setup around the real 1.22 USD price, max profit/loss, breakeven and when to use it. Educational.
ALLR technical analysis: range, last 1.22 USD, RSI 36.9, 52w range 1.03 USD–1.55 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ALLR in?
Allarity Therapeutics (ALLR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ALLR in an uptrend or downtrend?
As of 2026-09-11, ALLR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ALLR's trailing P/E ratio?
ALLR's trailing P/E is -1.78, with a market cap of 0.02B. See the earnings research page for full valuation detail.
When does ALLR next report earnings?
ALLR is next scheduled to report earnings on 2026-08-21, with a consensus EPS estimate of -0.25 USD.